Prognostic index for cutaneous melanoma:: an analysis after follow-up of 2715 patients

被引:21
作者
Schmid-Wendtner, MH
Baumert, J
Schmidt, M
Plewig, G
Volkenandt, M
Hölzel, D
机构
[1] Univ Munich, Dept Dermatol & Allergol, D-80337 Munich, Germany
[2] Univ Munich, Dept Med Informat Biometry & Epidemiol, Tumor Registry, D-80337 Munich, Germany
关键词
follow-up; cutaneous melanoma; prognostic index;
D O I
10.1097/00008390-200112000-00008
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In 2715 of 4524 patients with cutaneous melanoma treated surgically between 1968 and 1992 prognostic parameters were analysed for their value in predicting the occurrence of first progression. All of the 2715 patients developed only one invasive cutaneous melanoma during the follow-up period. Data concerning tumour thickness and mitotic index (maximum number of mitoses per square millimetre) of the cutaneous melanomas were determined. Between the characteristics age, tumour thickness, mitotic index, prognostic index (PI), sex, site of tumour, melanoma subtype and Clark level, the value of the mitotic index, as a prognostic parameter independent of tumour thickness, and the combination of mitotic index and tumour thickness were evaluated. The development of the first metastases was documented during a mean follow-up of 7.5 years. The majority of first recurrences occurred at regional lymph nodes and attempts have been made to identify those patients at risk of developing metastatic disease. The most effective parameters proved to be tumour thickness and mitotic index. For both parameters an independent prognostic influence was shown. The prognostic index, defined as the product of tumour thickness and number of mitoses per square millimetre, was re-evaluated and confirmed. A now modified prognostic index, defined as the product of square tumour thickness and mitotic index, proved to be even more useful for defining a subgroup of patients who are at risk of developing metastases and, therefore, might benefit from adjuvant therapy. (C) 2001 Lippincott Williams & Wilkins.
引用
收藏
页码:619 / 626
页数:8
相关论文
共 27 条
[2]  
CLARK WH, 1969, CANCER RES, V29, P705
[3]  
COCHRAN AJ, 1968, LANCET, V2, P1062
[4]   PROGNOSTIC FACTORS FOR MELANOMA PATIENTS WITH LESIONS 0.76-1.69 MM IN THICKNESS - AN APPRAISAL OF THIN LEVEL-IV LESIONS [J].
DAY, CL ;
MIHM, MC ;
SOBER, AJ ;
HARRIS, MN ;
KOPF, AW ;
FITZPATRICK, TB ;
LEW, RA ;
HARRIST, TJ ;
GOLOMB, FM ;
POSTEL, A ;
HENNESSEY, P ;
GUMPORT, SL ;
RAKER, JW ;
MALT, RA ;
COSIMI, AB ;
WOOD, WC ;
ROSES, DF ;
GORSTEIN, F ;
RIGEL, D ;
FRIEDMAN, RJ ;
MINTZIS, MM .
ANNALS OF SURGERY, 1982, 195 (01) :30-34
[5]   PROGNOSIS IN MALIGNANT-MELANOMA [J].
DAY, CL ;
SOBER, AJ ;
FITZPATRICK, TB ;
LEW, RA ;
MIHM, MC .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1980, 3 (05) :525-526
[6]   Multi-institutional melanoma lymphatic mapping experience: The prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients [J].
Gershenwald, JE ;
Thompson, W ;
Mansfield, PF ;
Lee, JE ;
Colome, MI ;
Tseng, CH ;
Lee, JJ ;
Balch, CM ;
Reintgen, DS ;
Ross, MI .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (03) :976-983
[7]   Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1•5 mm without clinically detectable node metastases [J].
Grob, JJ ;
Dreno, B ;
de la Salmonière, P ;
Delaunay, M ;
Cupissol, D ;
Guillot, B ;
Souteyrand, P ;
Sassolas, B ;
Cesarini, JP ;
Lionnet, S ;
Lok, C ;
Chastang, C ;
Bonerandi, JJ .
LANCET, 1998, 351 (9120) :1905-1910
[8]  
KAPELANSKI D P, 1979, Annals of Surgery, V189, P225, DOI 10.1097/00000658-197902000-00015
[9]  
KELLER D, 1985, Z HAUTKRANKHEITEN, V60, P297
[10]   High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of Intergroup trial E1694/S9512/C509801 [J].
Kirkwood, JM ;
Ibrahim, JG ;
Sosman, JA ;
Sondak, VK ;
Agarwala, SS ;
Ernstoff, MS ;
Rao, U .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (09) :2370-2380